Mounting evidence suggests that RAF-mediated MEK activation plays a crucial role in paradox MAPK (re)activation, leading to resistance and therapeutic failure with agents hitting a single step along the MAPK cascade.
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models / Del Curatolo, Anais; Conciatori, Fabiana; Cesta Incani, Ursula; Bazzichetto, Chiara; Falcone, Italia; Corbo, Vincenzo; D’Agosto, Sabrina; Eramo, Adriana; Sette, Giovann i; Sperduti, Isabella; De Luca, Teresa; Marabese, Mirko; Shirasawa, Senji; De Maria, Ruggero; Scarpa, Aldo; Broggini, Massimo; Del Bufalo, Donatella; Cognetti, Francesco; Milella, Michele; Ciuffreda, Ludovica. - In: JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH. - ISSN 1756-9966. - 37:1(2018). [10.1186/s13046-018-0820-5]
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
Del Curatolo, Anais;Conciatori, Fabiana;Cesta Incani, Ursula;Bazzichetto, Chiara;Sperduti, Isabella;De Maria, Ruggero;Cognetti, Francesco;Milella, Michele;
2018
Abstract
Mounting evidence suggests that RAF-mediated MEK activation plays a crucial role in paradox MAPK (re)activation, leading to resistance and therapeutic failure with agents hitting a single step along the MAPK cascade.| File | Dimensione | Formato | |
|---|---|---|---|
|
Del-Curatolo_Therapeutic_2018.pdf
accesso aperto
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Altra licenza (allegare)
Dimensione
3.89 MB
Formato
Adobe PDF
|
3.89 MB | Adobe PDF |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
